Copy to clipboard 
Amplitude Surgical posted FY2Q19 revenue of €27.6MM (USD $31.7MM) for the three-month period ending December 31, 2018, growth of +4.1% vs. FY2Q18. Domestic sales in France led the way with 7% growth, partially driven by increasing sales of Novastep foot and ankle products. Overall, France accounts for 60% of Amplitude’s business.
While international sales dipped very slightly for the quarter, sales were especially strong for the first half of the fiscal year in key markets like Brazil and Australia. The company continues to focus on the U.S. as a key strategic market where it is building commercial momentum and expects to hit $2MM in hip and knee sales for the full fiscal year.
ORTHOWORLD estimates quarter segment sales and growth on an as-reported basis as follows.
| FY2Q19 | FY2Q18 | $ Change | % Change | |
| Joint Replacement | $30.4 | $30.2 | $0.2 | 0.6% |
| Knees | $16.7 | $16.3 | $0.4 | 2.7% |
| Hips | $11.9 | $12.1 | -$0.3 | -2.1% |
| Extremities | $1.8 | $1.8 | $0.0 | -0.2% |
| Sports Medicine | $1.0 | $0.0 | $1.0 | |
| Orthobiologics | $0.3 | $0.2 | $0.1 | 73.6% |
| Total | $31.7 | $30.4 | $1.3 | 4.1% |
| FY1H19 | FY1H18 | $ Change | % Change | |
| Joint Replacement | $51.9 | $50.9 | $1.0 | 2.0% |
| Knees | $28.6 | $27.5 | $1.1 | 4.2% |
| Hips | $20.2 | $20.5 | -$0.3 | -1.5% |
| Extremities | $3.2 | $3.0 | $0.2 | 6.5% |
| Sports Medicine | $1.6 | $0.0 | $1.6 | |
| Orthobiologics | $0.5 | $0.4 | $0.1 | 38.2% |
| Total | $54.1 | $51.3 | $2.8 | 5.5% |
*Amplitude entered the Sports Medicine segment in December 2017.
Amplitude’s revenue by geographic region is as follows.
| Geographic Region | FY1Q19 | FY1Q18 | $ Change | % Change |
| France | $21.18 | $19.79 | $1.4 | 7.0% |
| International | $10.5 | $10.6 | -$0.1 | -1.3% |
| Subsidiaries | $7.79 | $7.79 | $0.0 | 0.0% |
| Distributors | $2.70 | $2.83 | -$0.1 | -4.8% |
| Total | $31.7 | $30.4 | $1.3 | 4.1% |
Sources: Amplitude Surgical; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
Amplitude Surgical posted FY2Q19 revenue of €27.6MM (USD $31.7MM) for the three-month period ending December 31, 2018, growth of +4.1% vs. FY2Q18. Domestic sales in France led the way with 7% growth, partially driven by increasing sales of Novastep foot and ankle products. Overall, France accounts for 60% of Amplitude’s business.
While...
Amplitude Surgical posted FY2Q19 revenue of €27.6MM (USD $31.7MM) for the three-month period ending December 31, 2018, growth of +4.1% vs. FY2Q18. Domestic sales in France led the way with 7% growth, partially driven by increasing sales of Novastep foot and ankle products. Overall, France accounts for 60% of Amplitude’s business.
While international sales dipped very slightly for the quarter, sales were especially strong for the first half of the fiscal year in key markets like Brazil and Australia. The company continues to focus on the U.S. as a key strategic market where it is building commercial momentum and expects to hit $2MM in hip and knee sales for the full fiscal year.
ORTHOWORLD estimates quarter segment sales and growth on an as-reported basis as follows.
| FY2Q19 | FY2Q18 | $ Change | % Change | |
| Joint Replacement | $30.4 | $30.2 | $0.2 | 0.6% |
| Knees | $16.7 | $16.3 | $0.4 | 2.7% |
| Hips | $11.9 | $12.1 | -$0.3 | -2.1% |
| Extremities | $1.8 | $1.8 | $0.0 | -0.2% |
| Sports Medicine | $1.0 | $0.0 | $1.0 | |
| Orthobiologics | $0.3 | $0.2 | $0.1 | 73.6% |
| Total | $31.7 | $30.4 | $1.3 | 4.1% |
| FY1H19 | FY1H18 | $ Change | % Change | |
| Joint Replacement | $51.9 | $50.9 | $1.0 | 2.0% |
| Knees | $28.6 | $27.5 | $1.1 | 4.2% |
| Hips | $20.2 | $20.5 | -$0.3 | -1.5% |
| Extremities | $3.2 | $3.0 | $0.2 | 6.5% |
| Sports Medicine | $1.6 | $0.0 | $1.6 | |
| Orthobiologics | $0.5 | $0.4 | $0.1 | 38.2% |
| Total | $54.1 | $51.3 | $2.8 | 5.5% |
*Amplitude entered the Sports Medicine segment in December 2017.
Amplitude’s revenue by geographic region is as follows.
| Geographic Region | FY1Q19 | FY1Q18 | $ Change | % Change |
| France | $21.18 | $19.79 | $1.4 | 7.0% |
| International | $10.5 | $10.6 | -$0.1 | -1.3% |
| Subsidiaries | $7.79 | $7.79 | $0.0 | 0.0% |
| Distributors | $2.70 | $2.83 | -$0.1 | -4.8% |
| Total | $31.7 | $30.4 | $1.3 | 4.1% |
Sources: Amplitude Surgical; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
